Literature DB >> 2858282

Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease.

S E Bruce, I Bjarnason, T J Peters.   

Abstract

By use of a radiometric assay transglutaminase activity was demonstrated for the first time in human jejunal mucosa. The activity is similar to that in other tissues, with a pH optimum of 9.0, an absolute requirement for Ca2+ and an apparent Km for putrescine of 0.15 mmol/l. Assay of jejunal transglutaminase activity with a variety of dietary proteins as acceptors showed high activity with gliadin, comparable with that of the standard substrate, dimethylcasein. Deamidation of the gliadin markedly reduced its acceptor activity. Collagen, ovalbumin, elastin and zein exhibited very low acceptor activities. Increased transglutaminase activity was demonstrated in jejunal biopsies from four patients with untreated coeliac disease compared with 14 control subjects and eight patients with inflammatory bowel disease. Eight patients with coeliac disease in remission, with normal levels of brush border alpha-glucosidase, showed elevated transglutaminase activities compared with those of controls. It is postulated that intestinal transglutaminase activity may be important in gliadin binding to tissues and thus in the pathogenesis of coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858282     DOI: 10.1042/cs0680573

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  35 in total

1.  Anti-endomysial antibody negative celiac disease: does additional serological testing help?

Authors:  A Dahele; K Kingstone; J Bode; D Anderson; S Ghosh
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

Review 2.  Ages of celiac disease: from changing environment to improved diagnostics.

Authors:  Alberto Tommasini; Tarcisio Not; Alessandro Ventura
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

3.  Transglutaminase and coeliac disease: endomysial reactivity and small bowel expression.

Authors:  G Brusco; P Muzi; R Ciccocioppo; F Biagi; M G Cifone; G R Corazza
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 4.  Celiac disease: from etiological factors to evolving diagnostic approaches.

Authors:  Anantdeep Kaur; Olga Shimoni; Michael Wallach
Journal:  J Gastroenterol       Date:  2017-06-19       Impact factor: 7.527

5.  Dietary modifications: food dependent autoimmunity in coeliac disease.

Authors:  A M Mowat
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

6.  Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.

Authors:  G D'Argenio; V Cosenza; G Riegler; N Della Valle; F Deritis; G Mazzacca
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

7.  Studies of intestinal lymphoid tissue. XIV--HLA status, mucosal morphology, permeability and epithelial lymphocyte populations in first degree relatives of patients with coeliac disease.

Authors:  M N Marsh; I Bjarnason; J Shaw; A Ellis; R Baker; T J Peters
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

8.  Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.

Authors:  G D'Argenio; M Calvani; N Della Valle; V Cosenza; G Di Matteo; P Giorgio; S Margarucci; O Petillo; F P Jori; U Galderisi; G Peluso
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

9.  Deamidation of gliadin peptides in lamina propria: implications for celiac disease.

Authors:  H Skovbjerg; D Anthonsen; E Knudsen; H Sjöström
Journal:  Dig Dis Sci       Date:  2008-08-05       Impact factor: 3.199

10.  A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.

Authors:  Joonhong Sohn; Ju Byung Chae; Sun Young Lee; Soo-Youl Kim; June-Gone Kim
Journal:  Korean J Ophthalmol       Date:  2010-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.